MPLT Stock Forecast: MapLight Therapeutics, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for MapLight Therapeutics, Inc. is $25. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 16 of 100 as at 21 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores MapLight Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (70): Analysts have, on balance, been raising their forecasts.
Momentum (1): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
MPLT stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on MPLT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Of the 20 most recent actions, 3 moved their price target up and 5 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 17 Nov 2026 | Canaccord Genuity | Maintains | Buy | $21 |
| 6 Oct 2026 | Guggenheim | Initiates | Neutral | — |
| 31 Aug 2026 | Needham | Maintains | Buy | $45 → $43 |
| 10 Aug 2026 | UBS | Downgrade | Neutral | $52 → $13 |
| 28 July 2026 | Canaccord Genuity | Maintains | Buy | $43 → $24 |
| 28 July 2026 | HC Wainwright & Co. | Maintains | Buy | $45 → $26 |
| 28 July 2026 | Morgan Stanley | Downgrade | Equal-Weight | $34 → $21 |
| 25 July 2026 | Canaccord Genuity | Maintains | Buy | — |
| 24 July 2026 | Canaccord Genuity | Maintains | Buy | $35 → $43 |
| 21 July 2026 | BMO Capital | Initiates | Outperform | $46 |
| 21 July 2026 | UBS | Maintains | Buy | $48 → $52 |
| 10 July 2026 | Needham | Maintains | Buy | $42 → $45 |
| 25 June 2026 | Raymond James | Initiates | Strong Buy | — |
| 23 June 2026 | Craig-Hallum | Maintains | Buy | — |
| 22 June 2026 | Needham | Maintains | Buy | — |
| 2 June 2026 | Stifel | Maintains | Buy | — |
| 28 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 27 May 2026 | UBS | Initiates | Buy | — |
| 21 May 2026 | Craig-Hallum | Initiates | Buy | — |
| 4 May 2026 | HC Wainwright & Co. | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for MPLT.
This page is one stock. Monday covers all of them.
MPLT appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
MPLT vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, MapLight Therapeutics, Inc. returned −55.3% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
MPLT analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 0.7×
- EV / EBITDA
- —
Cheaper than 79% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −74.2%
- Return on assets
- −45.4%
- Dividend yield
- —
Higher than 17% of US stocks
Higher than 9% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
MapLight Therapeutics, Inc. has a market value of $330.1M and an enterprise value of $51.5M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$229.8M.
Diluted earnings per share, trailing twelve months: −$5.84.
Free cash flow in the twelve months to 30 June 2026: −$175.1M.
MapLight Therapeutics, Inc. employs 133 people.
Data provided by Twelve Data
MPLT and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at MPLT’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own MapLight Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about MPLT
What is the MPLT stock price forecast for 2026-2027?
The median 12-month analyst price target for MapLight Therapeutics, Inc. is $25, with estimates ranging from $13 to $43. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is MPLT stock a buy right now?
Of the 15 analysts covering MapLight Therapeutics, Inc., 12 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks MapLight Therapeutics, Inc. 16 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank MPLT?
As at 21 Nov 2026, MapLight Therapeutics, Inc. ranks 16 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (70 of 100).
Will MPLT stock go up?
No one can know that. What the data says: the median 12-month target from 15 analysts is $25, and Ticker Nerd's factor model ranks MapLight Therapeutics, Inc. 16 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the MPLT stock forecast for 2030?
No analyst covering MapLight Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MPLT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $13 to $43 over the next 12 months.
How has MPLT stock performed over the past year?
MapLight Therapeutics, Inc. returned -55.3% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does MapLight Therapeutics, Inc. do?
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. The company’s current pipeline centers on brain and neuroscience programs aimed at conditions such as schizophrenia, Alzheimer’s disease psychosis, autism spectrum disorder, Parkinson’s disease motor symptoms, and other neuropsychiatric disorders.
About MapLight Therapeutics, Inc.
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. The company’s current pipeline centers on brain and neuroscience programs aimed at conditions such as schizophrenia, Alzheimer’s disease psychosis, autism spectrum disorder, Parkinson’s disease motor symptoms, and other neuropsychiatric disorders. Its lead candidate, ML-007C-MA, is being developed as an oral fixed-dose combination therapy, while additional product candidates include ML-004, ML-021, ML-055, and ML-009. MapLight Therapeutics also uses a discovery platform designed to identify neural circuits linked to disease and guide therapeutic modulation. The company is based in Redwood City, California, and focuses on translating circuit-based neuroscience into targeted medicines for patients with serious brain disorders.
CEO Dr. Christopher A. Kroeger M.B.A., M.D., Ph.D. · 133 employees · United States · https://www.maplightrx.com